Batch 001 - Live Allocation

Next Release: Aug 2026

Vivre Labs

Institutional Longevity

Catalogue
Single-vial Blends · one injection
Clinical Details

- Peptides -

- Single-vial Blends -

- Goals -

- Clinical Reference -

- Guides -

- Integrity -

◇ Compound Reference

GHRPInvestigationalPopular

Ipamorelin

Ghrelin Mimetic · 10mg

Status

Investigational

Route

SubQ

Half-life

~2 hours plasma

Class

Ghrelin-receptor agonist

MechanismSelective GHS-R Agonism

Cohort89 active prescriptions

Educational reference only - not a prescription or dosing recommendation. Some compounds are investigational or used off-label; suitability, dose, and monitoring are determined by your supervising physician. See Informed Consent & Disclaimer.

V-Series Member

$70 USD/vial

À-la-carte: $80 USD/vial · Save 13%

Vials per allocation

Member total (1×)$70

À-la-carte total$80

Flat per-vial pricing. Quantity is allocated and dispensed within your physician-supervised protocol - not a direct sale.

What this is

Selective growth hormone secretagogue. Minimal impact on cortisol or prolactin. Standard pairing with CJC-1295 in GH-optimization stacks.

Ghrelin Mimetic · 10mg per vial · dispensed after a physician review.

◇

Janoshik Verified

HPLC + MS purity, every batch

Independent third-party lab

⬡

COA Per Batch

Lot-level certificates published

Labeled vs actual mg disclosed

⊙

Protocol Reviewed

Used in V-Series clinical stacks

Phase 1 supervision onboarding

Ipamorelin · GHRP

◆ Certificate of Analysis · Ipamorelin

JANOSHIK ANALYTICALHPLC + MS · Independent third-party

Lot-specific COAs for Ipamorelin are published with each batch release. Sample certificates available on request via partnerships@vivrelabs.com.

◉

Clinical Overview

Ipamorelin

Ipamorelin is a 5-amino-acid synthetic GHRP (Growth Hormone Releasing Peptide) and selective ghrelin receptor agonist. Distinguished from earlier GHRPs by minimal effect on cortisol or prolactin, which makes it a preferred pairing partner for GHRH analogs.

✦

Selective GHS-R Agonism

Selective ghrelin-receptor agonist; releases GH via a distinct pathway.

❖

Synergy

Complements GHRH analogs (e.g. CJC-1295) without redundancy.

◈

Selectivity

Minimal off-target effect on cortisol/prolactin.

◈

Mechanism

How It Works

Selective ghrelin receptor (GHS-R) agonism. Stimulates GH release through a different pathway than GHRH analogs, creating synergy when paired.

Minimal off-target effects vs. earlier GHRPs.

✚

Patient Bloodwork Guide

Bloodwork for Growth-Hormone Protocols

GHRH / GHRP secretagogues - Tesamorelin, CJC-1295, Ipamorelin, V-G1

These protocols gently restore your body’s own pulsing release of growth hormone rather than replacing it. Because growth hormone also affects blood sugar, monitoring confirms two things: that it is working, and that it is doing so safely.

Incremental approach. Vivre starts below the standard dose and advances only on tolerance. This monitoring is the safety scaffold for that conservative approach.

Is it working? (Efficacy)

IGF-1The main signal of your overall growth-hormone output across the day.

IGFBP-3The protein that carries IGF-1 - measured alongside it for a clearer picture of how much is active.

Blood sugar & metabolism (watch closely)

Fasting insulinThe earliest warning sign of insulin resistance - it moves before blood sugar does.

HbA1cYour average blood sugar over ~3 months. Especially relevant with Tesamorelin.

Fasting glucoseA routine blood-sugar check.

Keeping side effects in check

ProlactinIpamorelin (the one Vivre uses) is highly selective and rarely affects this; checked as good practice.

Cortisol (AM)A stress-hormone check included for completeness.

Overall safety

hs-CRPA sensitive inflammation marker - confirms recovery, not strain.

CBC & CMPStandard blood count, liver, and kidney panels.

When the tests happen

Baseline (before you start)Full panel - your natural starting point.

Mid-cycle (week 6–8)IGF-1, fasting insulin, prolactin/cortisol - confirm it works, catch sugar drift early.

Post-cycle (4 weeks off)IGF-1 and fasting insulin - confirm natural production recovers.

Educational only - not medical advice or a dosing instruction. Your physician orders the tests, sets your dose, interprets results, and decides if a protocol is right for you. See the Informed Consent & Disclaimer for full terms.

⊞

Technical Profile

Measurable Properties

Class	Selective ghrelin-receptor (GHS-R) agonist / GH secretagogue
Mechanism	GHS-R agonism; stimulates GH with relative selectivity (limited cortisol/prolactin effect)
Terminal half-life	Short (~2 hours order)
Metabolism	Peptidase degradation
Evidence base	Moderate; selectivity profile relatively well-described
Regulatory status	Not an approved therapy; physician-supervised use only

Certificate of Analysis (per batch)

Analytical method: UHPLC-MS. Batch COA available on request - link to be populated per shipment.

COA link - pending per batch

Selectivity reasonably characterised; human outcome data limited. Educational only.

Clinical Literature

Peer-Reviewed References

Ipamorelin, the first selective growth hormone secretagogue

Raun K, Hansen BS, Johansen NL, et al. · 1998 · European Journal of Endocrinology 1998;139(5):552–561

▾

Findings

Foundational preclinical and early clinical study establishing Ipamorelin's selectivity profile. In swine, no GH secretagogue tested affected FSH, LH, PRL, or TSH plasma levels - but GHRP-6 and GHRP-2 elevated ACTH and cortisol meaningfully, while Ipamorelin did not (even at doses 200-fold above the ED50 for GH release). This selectivity is the principal clinical reason Ipamorelin is preferred in modern GH-axis stacks over earlier GHRPs.

View on publisher ↗

Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats

Johansen PB, Segev Y, Landau D, Phillip M, Flyvbjerg A · 1999 · Growth Hormone & IGF Research 1999;9(2):106–113

▾

Findings

Preclinical rat study examining downstream skeletal effects of Ipamorelin-driven GH release. Demonstrated dose-dependent increases in longitudinal bone growth via the GH/IGF-1 axis. Important methodology framing: rat model with pre-pubertal skeletal growth - does not translate directly to adult human use, but supports the IGF-1 elevation mechanism that anchors body-composition and recovery applications.

View on publisher ↗

Ipamorelin's selectivity profile is reasonably well-characterised (Raun 1998 swine model documented selective GH release without ACTH, cortisol, or prolactin elevation). Larger long-term outcome data in healthy adults remain limited - the human PK/PD studies are small (n<20) and there is no published large-cohort weight-loss or body-composition RCT. Important regulatory note: Ipamorelin is on the World Anti-Doping Agency (WADA) Prohibited List as a growth hormone secretagogue. Competitive athletes subject to drug testing should not use Ipamorelin - the metabolite is detectable in urine for at least 20 hours post-administration. Use at Vivre is within physician-supervised protocols with defined monitoring.

◇

Clinical Applications

Indications

GH optimization (paired with CJC-1295)
Body composition support
Recovery protocols
Age-related GH decline

⊙

Pharmacokinetics

Half-Life & Duration of Action

Half-life is how long a compound stays at active plasma concentration in your body. Most peptides in this catalogue have short plasma half-lives - they clear from your bloodstream within hours, sometimes minutes. The long-half-life compounds in this catalogue are the approved-class incretins (Tirzepatide, Semaglutide, Retatrutide), which are designed for once-weekly dosing - that's the molecular engineering choice that makes weekly dosing work.

Plasma Half-Life

~2 hours plasma (Springer Pharmaceutical Research, healthy volunteer trial). GH-releasing effect is a single discrete pulse; selectivity profile means no cortisol or prolactin elevation.

Why this matters for you

If you don't tolerate a compound or need to discontinue a protocol, short-half-life peptides are out of your bloodstream within hours - not days or weeks. That said, the biological effects they initiate (tissue repair signalling, mitochondrial signalling, gene expression changes) often persist longer than the peptide itself, through downstream cellular cascades. This is normal peptide pharmacology and is important context - the molecule clears fast, but the biology takes longer to wind down.

Evidence Base

Established clinical use in compounding pharmacy practice. Limited large-scale human trials.

Dosing protocols, administration frequency, and titration schedules are physician-determined at consultation - not published on these public pages. Vivre maintains a separate internal clinical reference for treating physicians.

◎

Commonly Paired

Compounds Often Prescribed With Ipamorelin

Clinical co-allocation patterns observed in Vivre's allocation history. Pairings are not prescriptions - the physician determines suitability per patient at consultation.

Growth Hormone Secretagogue

CJC-1295 (No DAC)

GHRH Analog · 10mg

◆ GH-axis stack

Ipamorelin (selective ghrelin agonist) paired with CJC-1295 (GHRH analog) produces amplified pulsatile GH release. This pairing IS Vivre's V-G1 protocol - pre-blended at Jodomi.

View CJC-1295 (No DAC) detail →

Growth Hormone Secretagogue

Sermorelin

GHRH Analog · 10mg

◆ GHRH alternative

Pairs with sermorelin when physician prefers a shorter-acting GHRH analog than CJC-1295.

View Sermorelin detail →

READY TO PROCEED

Start with the Biological Audit

Ipamorelin is verified and lot-tested, dispensed following a Biological Audit. The Audit is complimentary for the Batch 001 cohort.

$70 USD/vial

Ipamorelin · Member rate